2. Academic Validation
  3. The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis

The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis

  • Cancer Res. 2016 Jun 15;76(12):3593-603. doi: 10.1158/0008-5472.CAN-16-0061.
Luisana Astudillo 1,  Thiago G Da Silva 1,  Zhiqiang Wang 1,  Xiaoqing Han 1,  Ke Jin 1,  Jeffrey VanWye 1,  Xiaoxia Zhu 1,  Kelly Weaver 1,  Taiji Oashi 2,  Pedro E M Lopes 2,  Darren Orton 3,  Leif R Neitzel 4,  Ethan Lee 4,  Ralf Landgraf 5,  David J Robbins 1,  Alexander D MacKerell Jr 2,  Anthony J Capobianco 6
Affiliations

Affiliations

  • 1 Molecular Oncology Program, Division of Surgical Oncology, Dewitt Daughtry Family Department of Surgery, University of Miami, Miami, Florida. Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida.
  • 2 Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland.
  • 3 StemSynergy Therapeutics, Inc., Miami, Florida.
  • 4 Department of Cell and Developmental Biology and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • 5 Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida. Department of Biochemistry and Molecular Biology, University of Miami, Miami, Florida.
  • 6 Molecular Oncology Program, Division of Surgical Oncology, Dewitt Daughtry Family Department of Surgery, University of Miami, Miami, Florida. Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida. tcapobianco@med.miami.edu.
PMID: 27197169 DOI: 10.1158/0008-5472.CAN-16-0061
Abstract

In many cancers, aberrant Notch activity has been demonstrated to play a role in the initiation and maintenance of the neoplastic phenotype and in Cancer Stem Cells, which may allude to its additional involvement in metastasis and resistance to therapy. Therefore, Notch is an exceedingly attractive therapeutic target in Cancer, but the full range of potential targets within the pathway has been underexplored. To date, there are no small-molecule inhibitors that directly target the intracellular Notch pathway or the assembly of the transcriptional activation complex. Here, we describe an in vitro assay that quantitatively measures the assembly of the Notch transcriptional complex on DNA. Integrating this approach with computer-aided drug design, we explored potential ligand-binding sites and screened for compounds that could disrupt the assembly of the Notch transcriptional activation complex. We identified a small-molecule inhibitor, termed Inhibitor of Mastermind Recruitment-1 (IMR-1), that disrupted the recruitment of Mastermind-like 1 to the Notch transcriptional activation complex on chromatin, thereby attenuating Notch target gene transcription. Furthermore, IMR-1 inhibited the growth of Notch-dependent cell lines and significantly abrogated the growth of patient-derived tumor xenografts. Taken together, our findings suggest that a novel class of Notch inhibitors targeting the transcriptional activation complex may represent a new paradigm for Notch-based Anticancer therapeutics, warranting further preclinical characterization. Cancer Res; 76(12); 3593-603. ©2016 AACR.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z